-
1
-
-
78651087067
-
The changing epidemiology of type 1 diabetes: why is it going through the roof?
-
Vehik, K, Dabelea, D, The changing epidemiology of type 1 diabetes: why is it going through the roof?. Diabetes Metab Res Rev 27 (2011), 3–13.
-
(2011)
Diabetes Metab Res Rev
, vol.27
, pp. 3-13
-
-
Vehik, K.1
Dabelea, D.2
-
2
-
-
84921374064
-
The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus
-
Vallon, V, The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66 (2015), 255–270.
-
(2015)
Annu Rev Med
, vol.66
, pp. 255-270
-
-
Vallon, V.1
-
3
-
-
84946497765
-
Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes
-
Saulsberry, WJ, Coleman, CI, Mearns, ES, et al. Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes. Int J Clin Pract 69 (2015), 1221–1235.
-
(2015)
Int J Clin Pract
, vol.69
, pp. 1221-1235
-
-
Saulsberry, W.J.1
Coleman, C.I.2
Mearns, E.S.3
-
4
-
-
0021776150
-
Diabetes mellitus. Report of a WHO Study Group
-
Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 727 (1985), 1–113.
-
(1985)
World Health Organ Tech Rep Ser
, vol.727
, pp. 1-113
-
-
-
5
-
-
84934442921
-
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study
-
Henry, RR, Rosenstock, J, Edelman, S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 38 (2015), 412–419.
-
(2015)
Diabetes Care
, vol.38
, pp. 412-419
-
-
Henry, R.R.1
Rosenstock, J.2
Edelman, S.3
-
6
-
-
84942258219
-
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)
-
Pieber, TR, Famulla, S, Eilbracht, J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 17 (2015), 928–935.
-
(2015)
Diabetes Obes Metab
, vol.17
, pp. 928-935
-
-
Pieber, T.R.1
Famulla, S.2
Eilbracht, J.3
-
7
-
-
84939621365
-
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes
-
Sands, AT, Zambrowicz, BP, Rosenstock, J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 38 (2015), 1181–1188.
-
(2015)
Diabetes Care
, vol.38
, pp. 1181-1188
-
-
Sands, A.T.1
Zambrowicz, B.P.2
Rosenstock, J.3
-
8
-
-
84934446360
-
Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient
-
Bell, DS, Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient. Case Rep Endocrinol, 2015, 2015, 676191.
-
(2015)
Case Rep Endocrinol
, vol.2015
, pp. 676191
-
-
Bell, D.S.1
-
9
-
-
84887331142
-
Canagliflozin: improving diabetes by making urine sweet
-
Vouyiouklis, M, Canagliflozin: improving diabetes by making urine sweet. Cleve Clin J Med 80 (2013), 683–687.
-
(2013)
Cleve Clin J Med
, vol.80
, pp. 683-687
-
-
Vouyiouklis, M.1
-
10
-
-
77949680683
-
The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews
-
Kirkham, JJ, Dwan, KM, Altman, DG, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ, 340, 2010, c365.
-
(2010)
BMJ
, vol.340
, pp. c365
-
-
Kirkham, J.J.1
Dwan, K.M.2
Altman, D.G.3
-
11
-
-
84867559501
-
Relationship between fasting and 2-hour postprandial plasma glucose levels and vascular complications in patients with type 2 diabetes mellitus
-
Tanaka, M, Relationship between fasting and 2-hour postprandial plasma glucose levels and vascular complications in patients with type 2 diabetes mellitus. J Int Med Res 40 (2012), 1295–1303.
-
(2012)
J Int Med Res
, vol.40
, pp. 1295-1303
-
-
Tanaka, M.1
-
12
-
-
84884502673
-
SGLT inhibitors in management of diabetes
-
Tahrani, AA, Barnett, AH, Bailey, CJ, SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 1 (2013), 140–151.
-
(2013)
Lancet Diabetes Endocrinol
, vol.1
, pp. 140-151
-
-
Tahrani, A.A.1
Barnett, A.H.2
Bailey, C.J.3
-
13
-
-
84978976076
-
Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis
-
Palmer, SC, Mavridis, D, Nicolucci, A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316 (2016), 313–324.
-
(2016)
JAMA
, vol.316
, pp. 313-324
-
-
Palmer, S.C.1
Mavridis, D.2
Nicolucci, A.3
-
14
-
-
84959917974
-
The changing therapeutic armamentarium for patients with type 1 diabetes
-
Comee, M, Peters, A, The changing therapeutic armamentarium for patients with type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 23 (2016), 106–110.
-
(2016)
Curr Opin Endocrinol Diabetes Obes
, vol.23
, pp. 106-110
-
-
Comee, M.1
Peters, A.2
-
15
-
-
84951905769
-
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
-
Scheen, AJ, SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opin Drug Saf 14 (2015), 1879–1904.
-
(2015)
Expert Opin Drug Saf
, vol.14
, pp. 1879-1904
-
-
Scheen, A.J.1
-
16
-
-
84930580133
-
Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
-
Hinnen, D, Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab 6 (2015), 92–102.
-
(2015)
Ther Adv Endocrinol Metab
, vol.6
, pp. 92-102
-
-
Hinnen, D.1
-
17
-
-
85007514629
-
American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis
-
Handelsman, Y, Henry, RR, Bloomgarden, ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 22 (2016), 753–762.
-
(2016)
Endocr Pract
, vol.22
, pp. 753-762
-
-
Handelsman, Y.1
Henry, R.R.2
Bloomgarden, Z.T.3
|